Tag:
Daiichi Sankyo
Latest Headlines
Latest Headlines
With new plant, Ranbaxy back in force in North America
After a four-year stint of being unable to ship drugs from its plants in India to the U.S. and Canada, Ranbaxy Laboratories is returning in a big way.
GlaxoSmithKline, Daiichi Sankyo join forces to sell vaccines in Japan
GlaxoSmithKline ( $GSK ) and Daiichi Sankyo ( $D4S.BE ) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan.
GSK, Daiichi Sankyo aim to top Japan's vaccine market
GlaxoSmithKline ( $GSK ) and Daiichi Sankyo have signed a joint venture agreement to create what GSK believes will be the largest vaccines company in Japan.
GSK and Daiichi create joint development venture in Japan
GlaxoSmithKline ( $GSK ) and Japan's number three pharma company Daiichi Sankyo have created a joint venture to bring new treatments to the Japanese market.
GSK, Daiichi team to develop, launch vaccines in Japan
Just last week, GlaxoSmithKline ( $GSK ) CEO Andrew Witty ( photo ) slighted European markets by touting Japan as a superior place to sell drugs these days. Japan's moves to speed new drugs to market...
Ranbaxy CEO to ride out transformation under DOJ oversight
Arun Sawhney has signed a 5-year contract extension to bat cleanup for Ranbaxy Laboratories ( $RANBXY.NS ). For those not versed in baseball parlance, the Ranbaxy CEO has agreed to stick around during...
Daiichi shops India for bolt-on deals, ET says
Ranbaxy Laboratories hasn't delivered enough of Indian pharma to its majority owner, Daiichi Sankyo . The Japanese drugmaker is once again kicking tires in India, The Economic Times reports, almost
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
Ranbaxy, FDA enter consent decree over GMP, data breaches
Plans for the $500 million that Daiichi Sankyo set aside to get problem child Ranbaxy out of regulatory jail became clearer Wednesday with the filing of a consent decree. The Indian-based drugmaker
Daiichi sends in posse to keep Ranbaxy plant in line
Daiichi Sankyo isn't taking chances on Ranbaxy Laboratories ' ability to keep turning out FDA-compliant drugs. The Japanese drugmaker, which owns the controlling interest in the Indian company, has
